Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease

D. Grahame Hardie, Peter Tontonoz (Editor), Laszlo Nagy (Editor)

    Research output: Contribution to journalReview article

    166 Citations (Scopus)

    Abstract

    Obesity, type 2 diabetes and the metabolic syndrome are disorders of energy balance, which the AMP-activated protein kinase (AMPK) regulates both at the cellular and whole body levels. AMPK switches cells from an anabolic state where nutrients are taken up and stored, to a catabolic state where they are oxidized. Drugs that activate AMPK indirectly (metformin and thiazolidinediones) are now the mainstay of treatment for type 2 diabetes, but more direct AMPK activators may have fewer side effects. However, activating mutations in AMPK can cause heart disease, and it will be important to look for adverse effects in the heart. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

    Original languageEnglish
    Pages (from-to)81-89
    Number of pages9
    JournalFEBS Letters
    Volume582
    Issue number1
    DOIs
    Publication statusPublished - 9 Jan 2008

    Keywords

    • AMP-activated protein kinase
    • metabolic syndrome
    • diabetes
    • metformin
    • thiazolidinedione
    • ventricular pre-excitation
    • FATTY-ACID OXIDATION
    • SKELETAL-MUSCLE
    • INSULIN-RESISTANCE
    • GLUCOSE-TRANSPORT
    • 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE
    • RESPIRATORY-CHAIN
    • UPSTREAM KINASE
    • FOOD-INTAKE
    • C-ELEGANS
    • COMPLEX I

    Cite this